Williamson D J, Hill R G, Shepheard S L, Hargreaves R J
Department of Pharmacology, Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Harlow, Essex, CM20 2QR, UK.
Br J Pharmacol. 2001 Aug;133(7):1029-34. doi: 10.1038/sj.bjp.0704162.
These studies investigated the pharmacology of neurogenic dural vasodilation in anaesthetized guinea-pigs. Following introduction of a closed cranial window the meningeal (dural) blood vessels were visualized using intravital microscopy and the diameter constantly measured using a video dimension analyser. Dural blood vessels were constricted with endothelin-1 (3 microg kg(-1), i.v.) prior to dilation of the dural blood vessels with calcitonin gene-related peptide (CGRP; 1 microg kg(-1), i.v.) or local electrical stimulation (up to 300 microA) of the dura mater. In guinea-pigs pre-treated with the CGRP receptor antagonist CGRP((8-37)) (0.3 mg kg(-1), i.v.) the dilator response to electrical stimulation was inhibited by 85% indicating an important role of CGRP in neurogenic dural vasodilation in this species. Neurogenic dural vasodilation was also blocked by the 5-HT(1B/1D) agonist rizatriptan (100 microg kg(-1)) with estimated plasma levels commensurate with concentrations required for anti-migraine efficacy in patients. Rizatriptan did not reverse the dural dilation evoked by CGRP indicating an action on presynaptic receptors located on trigeminal sensory fibres innervating dural blood vessels. In addition, neurogenic dural vasodilation was also blocked by the selective 5-HT(1D) agonist PNU-142633 (100 microg kg(-1)) but not by the 5-HT(1F) agonist LY334370 (3 mg kg(-1)) suggesting that rizatriptan blocks neurogenic vasodilation via an action on 5-HT(1D) receptors located on perivascular trigeminal nerves to inhibit CGRP release. This mechanism may underlie one of the anti-migraine actions of the triptan class exemplified by rizatriptan and suggests that the guinea-pig is an appropriate species in which to investigate the pharmacology of neurogenic dural vasodilation.
这些研究调查了麻醉豚鼠中神经源性硬脑膜血管舒张的药理学特性。在开颅窗后,通过活体显微镜观察脑膜(硬脑膜)血管,并使用视频尺寸分析仪持续测量血管直径。在用降钙素基因相关肽(CGRP;1μg/kg,静脉注射)或硬脑膜局部电刺激(高达300μA)使硬脑膜血管舒张之前,先用内皮素-1(3μg/kg,静脉注射)使硬脑膜血管收缩。在用CGRP受体拮抗剂CGRP(8-37)(0.3mg/kg,静脉注射)预处理的豚鼠中,电刺激引起的舒张反应被抑制了85%,这表明CGRP在该物种的神经源性硬脑膜血管舒张中起重要作用。5-羟色胺(5-HT)1B/1D激动剂利扎曲普坦(100μg/kg)也可阻断神经源性硬脑膜血管舒张,其估计血浆水平与患者抗偏头痛疗效所需浓度相当。利扎曲普坦不能逆转CGRP引起的硬脑膜舒张,这表明其作用于支配硬脑膜血管的三叉神经感觉纤维上的突触前受体。此外,选择性5-HT1D激动剂PNU-142633(100μg/kg)也可阻断神经源性硬脑膜血管舒张,但5-HT1F激动剂LY334370(3mg/kg)则不能,这表明利扎曲普坦通过作用于血管周围三叉神经上的5-HT1D受体来抑制CGRP释放,从而阻断神经源性血管舒张。这种机制可能是利扎曲普坦等曲坦类药物抗偏头痛作用的基础之一,表明豚鼠是研究神经源性硬脑膜血管舒张药理学的合适物种。